Gregg Sherman, MD
Harvey C. Parker, Ph.D., CCMEP
National Association for Continuing Education
President, Creative Director
San Francisco, CA
Inflammatory bowel disease (IBD) is a term that encompasses chronic inflammatory disorders of the bowel, the most common of these being ulcerative colitis (UC) and Crohn's disease (CD). As many as 1.5 million persons in the United States may suffer from IBD accounting for over 700,000 physician visits, 100,000 hospitalizations, and disability in 119,000 patients every year in the United States. IBD is associated with an overall health care cost of more than $1.7 billion and adversely affects the quality of life of both patients and their families.
This program will help to bridge the knowledge and performance gaps related to identification, and management of Inflammatory Bowel Disease. This educational initiative offers a two-phased curriculum. Phase 1 offered a Self Assessment Program (SAP) to allow learners to assess their knowledge and skills in this area, compare their selections and scores with all other learners to date, and review commentary from the faculty. This is the Phase 2 activity in the program, and utilizes a case-based interactive structure focused on educational drivers identified in Phase 1.
DISCLOSURE POLICY STATEMENT:
It is the policy of NACE to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. NACE assesses conflict of interest with its faculty, planners and managers of CME activities. Conflicts of interest that are identified are resolved by reviewing that presenter's content for fair balance and absence of bias, scientific objectivity of studies utilized in this activity, and patient care recommendations.
While NACE endeavors to review faculty content, it remains the obligation of each physician or other healthcare practitioner to determine the applicability or relevance of the information provided from this course in his or her own practice.
DISCLOSURE OF CONFLICTS OF INTEREST:
Gerald W. Dryden, MD, MSPH, MSc, AGAF, FASGE, Course Director, has the follow to disclose: serves on the speaker’s bureaus of Abbvie, Takeda, EnteraHeatlh and Salix. Dr. Dryden also conducts contracted research for Abbvie, Johnson & Johnson, Merck, Takeda, Pfizer, and Genetech.
Millie D. Long, MD, MPH, serves as a consultant for Abbvie, Pfizer, Takeda and Theravance.
Gregg Sherman, MD, has no real or apparent conflicts of interest to report.
Harvey Parker, PhD, has no real or apparent conflicts of interest to report.
Josh Kilbridge has no real or apparent conflicts of interest to report.
DISCLOSURE OF UNLABELED USE:
NACE requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
The opinions expressed during the educational activity are those of the faculty and do not necessarily represent the views of NACE. The information is presented for the purpose of advancing the attendees' professional development.
For CME questions, please contact: NACE at email@example.com
Contact this CME provider for privacy and confidentiality policy statement information at:
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Association for Continuing Education designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This Enduring Material activity, Evolving Diagnostic and Treatment Strategies in Inflammatory Bowel Disease: Targeting Learning to Close Gaps and Improve Outcomes, has been reviewed and is acceptable for Prescribed credit by the American Academy of Family Physicians. Term of approval begins 09/15/2016. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 0.5 contact hours of continuing education (which includes 0.25 hrs of pharmacology).
TO OBTAIN CME CREDITS:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit.
- Nurse Practitioners who successfully complete the post-test and evaluation will receive AANP CE credit.
- You must score 60% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
COURSE FORMAT/MEDIUM: Internet CME Activity
ESTIMATED TIME TO COMPLETE: 30 minutes
This activity is sponsored by National Association for Continuing Education.